NCT00427999View on ClinicalTrials.gov

Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

June 30, 2015

Study Completion Date

August 31, 2015

Conditions
Prostate Cancer
Interventions
DRUG

imatinib mesylate

DRUG

Treosulfane

DRUG

etoricoxib

DRUG

pioglitazone

DRUG

dexamethasone

Trial Locations (10)

20246

Novartis Investigative Site, Hamburg

22607

Novartis Investigative Site, Hamburg

34131

Novartis Investigative Site, Kassel

53105

Novartis Investigative Site, Bonn

72076

Novartis Investigative Site, Tübingen

82152

Novartis Investigative Site, Planegg

83435

Novartis Investigative Site, Bad Reichenhall

93053

Novartis Investigative Site, Regensburg

94032

Novartis Investigative Site, Passau

04416

Novartis Investigative Site, Markkleeberg

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY